JP2017534673A - 精神病性障害を治療するための方法および組成物 - Google Patents

精神病性障害を治療するための方法および組成物 Download PDF

Info

Publication number
JP2017534673A
JP2017534673A JP2017533742A JP2017533742A JP2017534673A JP 2017534673 A JP2017534673 A JP 2017534673A JP 2017533742 A JP2017533742 A JP 2017533742A JP 2017533742 A JP2017533742 A JP 2017533742A JP 2017534673 A JP2017534673 A JP 2017534673A
Authority
JP
Japan
Prior art keywords
glutathione
nvhl
rats
ebselen
antipsychotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017533742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534673A5 (enExample
Inventor
ジョナサン キール
ジョナサン キール
Original Assignee
サウンド・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サウンド・ファーマシューティカルズ・インコーポレイテッド filed Critical サウンド・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2017534673A publication Critical patent/JP2017534673A/ja
Publication of JP2017534673A5 publication Critical patent/JP2017534673A5/ja
Priority to JP2021130488A priority Critical patent/JP2021181473A/ja
Priority to JP2023168970A priority patent/JP2023169413A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017533742A 2014-09-15 2015-09-15 精神病性障害を治療するための方法および組成物 Pending JP2017534673A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021130488A JP2021181473A (ja) 2014-09-15 2021-08-10 精神病性障害を治療するための方法および組成物
JP2023168970A JP2023169413A (ja) 2014-09-15 2023-09-29 精神病性障害を治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050635P 2014-09-15 2014-09-15
US62/050,635 2014-09-15
PCT/US2015/050255 WO2016044314A1 (en) 2014-09-15 2015-09-15 Methods and compositions for treating psychotic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021130488A Division JP2021181473A (ja) 2014-09-15 2021-08-10 精神病性障害を治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2017534673A true JP2017534673A (ja) 2017-11-24
JP2017534673A5 JP2017534673A5 (enExample) 2018-10-25

Family

ID=55533760

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017533742A Pending JP2017534673A (ja) 2014-09-15 2015-09-15 精神病性障害を治療するための方法および組成物
JP2021130488A Pending JP2021181473A (ja) 2014-09-15 2021-08-10 精神病性障害を治療するための方法および組成物
JP2023168970A Pending JP2023169413A (ja) 2014-09-15 2023-09-29 精神病性障害を治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021130488A Pending JP2021181473A (ja) 2014-09-15 2021-08-10 精神病性障害を治療するための方法および組成物
JP2023168970A Pending JP2023169413A (ja) 2014-09-15 2023-09-29 精神病性障害を治療するための方法および組成物

Country Status (7)

Country Link
US (3) US20170246148A1 (enExample)
EP (1) EP3194027A4 (enExample)
JP (3) JP2017534673A (enExample)
KR (2) KR20230107890A (enExample)
AU (4) AU2015317877A1 (enExample)
CA (1) CA2961380A1 (enExample)
WO (1) WO2016044314A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524963A (ja) * 2020-05-09 2023-06-14 深▲セン▼深見医薬科技有限公司 非定型抗精神病薬による副作用の治療

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6308134B2 (ja) * 2012-12-27 2018-04-11 ソニー株式会社 細胞分析システム、細胞分析プログラム及び細胞分析方法
EP3037514B1 (en) 2013-11-08 2018-12-26 Sony Corporation Cell analysis system, cell analysis program, and cell analysis method
KR102474830B1 (ko) * 2016-05-18 2022-12-06 사운드 파마슈티칼스 인코퍼레이티드 중이염의 치료
CN107362144B (zh) * 2017-08-03 2020-04-17 华侨大学 一种鲁拉西酮脑靶向脂质体注射剂及其制备方法
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
CN111432813B (zh) * 2017-11-14 2024-01-09 爱思开生物制药株式会社 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507696A (ja) * 1996-12-31 2001-06-12 アンチオキシダント ファーマシューティカルズ コーポレーション グルタチオンの医薬製剤およびその投与方法
JP2005508333A (ja) * 2001-09-27 2005-03-31 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 生理学的過程の調節およびこれに有用な薬剤
JP2008538586A (ja) * 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
JP2009513672A (ja) * 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
CA2842106A1 (en) * 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507696A (ja) * 1996-12-31 2001-06-12 アンチオキシダント ファーマシューティカルズ コーポレーション グルタチオンの医薬製剤およびその投与方法
JP2005508333A (ja) * 2001-09-27 2005-03-31 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 生理学的過程の調節およびこれに有用な薬剤
JP2008538586A (ja) * 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
JP2009513672A (ja) * 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J CLIN PSYCHOPHARMACOL., 2005, VOL.25 NO.L2, P.170-174, JPN6019039616, ISSN: 0004481915 *
NEURON, 2014 SEP 3, VOL.83 NO.5, P.1073-1084, JPN6020033076, ISSN: 0004481914 *
OXIDATIVE MED CELL LONGEVITY., 2012, VOL.2012, P.1-13(ARTICLE ID 609421), JPN6019039617, ISSN: 0004481911 *
PHARMACOL BIOCHEM BEHAVIOR, 2005, VOL.81, P.608-615, JPN6019039618, ISSN: 0004481912 *
PROG NEURO-PSYCHOPHARMACOL BIOL PSYCH., 2003, VOL.27, P.135-140, JPN6019039619, ISSN: 0004481913 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524963A (ja) * 2020-05-09 2023-06-14 深▲セン▼深見医薬科技有限公司 非定型抗精神病薬による副作用の治療
JP7595087B2 (ja) 2020-05-09 2024-12-05 深▲セン▼深見医薬科技有限公司 非定型抗精神病薬による副作用の治療

Also Published As

Publication number Publication date
AU2023200727A1 (en) 2023-03-09
AU2025201645A1 (en) 2025-03-27
US20210379017A1 (en) 2021-12-09
EP3194027A4 (en) 2018-04-18
JP2021181473A (ja) 2021-11-25
US20170246148A1 (en) 2017-08-31
CA2961380A1 (en) 2016-03-24
JP2023169413A (ja) 2023-11-29
KR20230107890A (ko) 2023-07-18
KR20170066432A (ko) 2017-06-14
AU2015317877A1 (en) 2017-05-04
AU2021200583A1 (en) 2021-03-04
EP3194027A1 (en) 2017-07-26
US20240050409A1 (en) 2024-02-15
WO2016044314A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
JP2023169413A (ja) 精神病性障害を治療するための方法および組成物
US11723911B2 (en) Treatment of demyelinating diseases
KR20180064373A (ko) 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
TW201444860A (zh) 脲嘧啶核苷衍生物、組合物及使用方法
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
JP7695246B2 (ja) アルツハイマー病の治療のための化合物
JP7100866B2 (ja) メニエール病の処置法
TR201908928T4 (tr) Parkinsoniyan sendromları olan nörodejeneratif hastalıkları tedavi etmek için bümetanid.
MD3897578T2 (ro) Regimuri de dozare pentru utilizarea LY3154207 în tratamentul tulburărilor dopaminergice ale SNC
EP2739274A1 (en) Treatment of cognitive impairment
US20230333087A1 (en) Methods for monitoring patient response to treatment of retinal oxidative diseases
WO2005123053A2 (en) Use of cb2 receptors agonists for the treatment of huntington’s disease
FR3077201A1 (fr) Derives aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prevention et le traitement des douleurs relatives au nerf trijumeau
Faakye Age-Related Cerebral Microhemorrhages: Prevention and Morphologies
KR20170018072A (ko) 편두통을 치료 또는 경감시키는 방법
JP5978472B2 (ja) 耳鳴患者の治療用の薬剤
Falah The role of the cdk5 pathway and NMDA receptor phosphorylation in neurodegeneration in hippocampal sclerosis
WO2015105064A1 (ja) 網膜疾患の予防又は治療のための医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210407